Actively Recruiting
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
Led by Acorn Biolabs Inc. · Updated on 2026-02-12
60
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.
CONDITIONS
Official Title
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be between 18 and 65 years old
- Male and female participants included, with up to 40 males and 20 females total
- Must have androgenic alopecia
- Must be on a stable course of minoxidil (oral or topical) and/or 5-alpha reductase inhibitors for at least 12 months prior to baseline
- Female participants must not have used hair growth medications or topical treatments for at least 6 months prior to baseline
- Participants on testosterone replacement therapy must have been on a stable course for at least 12 months
- Must have no intention to start new hair growth medications or change dosage of current minoxidil or 5-alpha reductase inhibitors during the study
- Must be willing and able to provide informed consent and attend all study visits
- Must be willing to tolerate multiple scalp injections
- Must be willing to maintain the same hairstyle throughout the study
- Must agree to have up to 5 small UV or red tattoo dots applied to the scalp for monitoring
You will not qualify if you...
- Diagnosis of alopecia areata or other non-androgenic alopecia
- Active scalp skin diseases like psoriasis or severe seborrheic dermatitis
- Scalp infections or cuts/abrasions
- Severe active systemic infections
- Surgical hair restoration within the last 12 months
- Current or recent malignancy within 5 years, except certain skin cancers
- History of systemic chemotherapy or radiation
- History of thyroid dysfunction or autoimmune disorders such as Graves disease, Hashimoto thyroiditis, or lupus
- Continuous daily use of NSAIDs or Vitamin E unless discontinued 7 days before first treatment
- Use of medications known to cause hair loss within the last 3 months
- Known allergy or sensitivity to tattoo ink
- Current anticoagulant therapy
- Significant tendency to develop keloids or hypertrophic scars
- Inability to communicate with study staff
- Any health condition deemed by the investigator to preclude participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ziering Medical
West Hollywood, California, United States, 90069
Actively Recruiting
Research Team
L
Lisa M Campbell, PhD
CONTACT
H
Heather Dwyer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here